|Publication number||US7123969 B1|
|Application number||US 10/443,240|
|Publication date||Oct 17, 2006|
|Filing date||May 21, 2003|
|Priority date||May 21, 2003|
|Publication number||10443240, 443240, US 7123969 B1, US 7123969B1, US-B1-7123969, US7123969 B1, US7123969B1|
|Original Assignee||Pacesetter, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (18), Referenced by (9), Classifications (5), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present invention generally relates to leads for connecting implantable medical devices with selected body tissue. More particularly, the invention relates to a low-polarization electrode for use with such leads.
As is well known, pacemakers are implanted in patients to deliver electrical stimulation pulses to the patient's heart via one or more electrodes mounted on one or more leads. In addition to being used to stimulate the patient's heart, the electrodes are also frequently used to sense electrical activity of the heart, often in response to the stimulation pulses. It would be desirable to use the same electrode both for stimulating the patient's heart and for sensing corresponding heart activity. However, delivering a stimulation pulse through an electrode results in what is referred to as lead polarization. Lead polarization is a post-stimulation artifact that results from an accumulation of charge at the electrode/tissue interface following an electrical stimulation pulse. This lead polarization (or “after-potential”) can hinder or even prevent the accurate sensing of intrinsic cardiac electrical activity that follows soon after the stimulation pulse (e.g., the evoked response of the heart tissue caused by the stimulation pulse). In some instances, the electrode or electrodes used to deliver the stimulation pulses are not able to discriminate between the after-potential and an evoked response signal, and therefore other electrodes must be used to detect cardiac activity. This requires the provision of additional electrodes that are relatively far from the site of interest, which is disadvantageous, and also requires a lead with additional components.
In modern pacing leads the electrodes, both of the tip and ring variety, often employ a surface coating of titanium nitride (TiN). The implementation of TiN as a coating material was an improvement in the pacing industry by providing an electrode/tissue interface with increased electrode/tissue capacitance. The increase in interface capacitance is a result of the increased active surface area brought about by the fractal morphology of the sputter-coated titanium nitride material. The increase in interface capacitance, in turn, lowers the polarization artifact typically seen following the pacing pulse. This falls out from the equation describing the after-potential or polarization given by equation (1), as follows.
RL: resistance of the lead
CH: Helmholtz capacitance
Ur: charge voltage
Uc: polarization value
Although the lowering of the polarization value can be achieved by increasing the lead length, which in turn increases RL (the resistance of the lead), it compromises the sensing functionality of the electrode and increases energy consumption. See Schaldach, “The Electrode-Electrolyte Interface”, Electrotherapy of the Heart, Spr-Vlg, 1992.
General disclosures of body implantable electrode constructions in which either or both of the leads and electrodes are constructed of titanium or titanium alloys are well known. Other implantable medical devices are known that include a pulse generator and associated electrodes designed to prevent leakage currents in the output circuit. This is accomplished by utilization of the electrode lead-to-tissue electrolytic interface capacitance (Helmholtz capacitance) with a highly leakage resistant layer interfaced together with and formed, for example, by titanium and titanium dioxide. Moreover, electrodes for muscle stimulation are known which feature a platinum electrode which has preferably been platinized to develop a coating of platinum black, contained in a second electrode housing of suitable electrode metal which is compatible with platinum such as titanium. Finally, the use of a platinum black coating with materials other than titanium are also known to reduce source impedance and polarization. Indeed, the use of a platinum black coating with titanium has long been known to reduce source impedance and polarization.
While advances have been made in the construction of leads that provide lower polarization values, there is still a need for leads that provide even lower polarization artifacts, particularly in the case of electrodes to be used to perform both pacing and sensing.
What is disclosed herein is an implantable lead for stimulating a heart that includes one or more electrodes that exhibit relatively low polarization values. The implantable lead includes one or more stimulating electrodes (e.g., a cathode electrode) that may directly contact heart tissue. The electrode is designed to provide low polarization values, which results in the electrode being suitable for use as both a pacing electrode and a sensing electrode. The lead further includes a suitable conductor connected to the electrode to provide stimulation energy to the electrode and to transmit electrical signals sensed by the electrode. The cathode electrode is comprised of a base substrate, an intermediate layer of a highly dielectric material, and a polarization reducing coating that is applied over the base substrate.
Other and further features, advantages, and benefits of the invention will become apparent in the following description taken in conjunction with the following drawings. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory but are not to be restrictive. The accompanying drawings which are incorporated in and constitute a part of this invention, illustrate one of the embodiments of the invention, and together with the description, serve to explain the principles of the invention in general terms. Like numerals refer to like parts throughout the disclosure.
The foregoing aspects and other features of the present invention are explained in the following description, taken in connection with the accompanying drawings, wherein:
Referring now to
The tissue stimulation system 8 includes a conventional implantable stimulation device 10. As is well known, stimulation device 10 interacts with a patient's heart (not shown) by way of one or more leads, such as lead 22. Lead 22 is suitable for delivering stimulation to a patient's heart via electrodes 34 and 39, and furthermore is capable of sensing electrical activity within the heart via electrodes 34 and 39, and delivering corresponding electrical signals to stimulation device 10 for processing. While only a single lead 22 is shown in
As is well known in the art, implantable stimulation device 10 is capable of treating fast and/or slow arrhythmias with stimulation therapy, including cardioversion, defibrillation, and/or pacing stimulation. A more detailed description of an implantable stimulation device with which the lead 22 may be utilized is found in U.S. Pat. No. 6,339,723, which is expressly incorporated herein by reference.
Implantable stimulation device 10 includes a housing 40 and a connector (or header) 41 connected to housing 40 and having a plurality of terminals (not shown) that provide electrical connections with the respective electrodes of lead 22, as is well known to those skilled in the art.
At the distal end of lead 22 is electrode 34 (i.e., tip electrode) and, in one embodiment, adjacent to electrode 34 is an anchor assembly 36 that carries a plurality of circumferentially spaced tines 38 (
In one embodiment, electrode 39 is connected to lead 22 and is spaced from the first electrode 34 a predetermined distance so as to provide bipolar pacing and/or sensing in conjunction with electrode 34 (
In one embodiment, lead 22 includes a pair of coiled, coaxial conductors 50 and 52 (
As shown in
In another embodiment, one or both of the conductors 50 and 52 may be in the form of cable or wire conductors. Again, electrical isolation may be achieved in various manners, as described above. Alternatively, both conductors may be in the form of cable or wire conductors.
In one embodiment, distal electrode 34 serves as the cathodal electrode, while the second electrode 39 serves as the anodal electrode for bipolar pacing and/or sensing.
Preferably, distal electrode 34 is formed of a multilayer construction. Referring to
The base substrate 60 is formed of a conductive, inert material, and preferably of platinum iridium. In one embodiment, base substrate 60 is formed of one or more members of the platinum group (also known as “platinum metals”, or the platinum-like metals in Group VIII of the Periodic Table of Elements), namely ruthenium, rhodium, palladium, osmium, iridium, platinum, as well as any combination thereof (e.g., an alloy of two or more of the listed metals). Alternatively, the base substrate 60 may be formed of titanium or any other suitable inert metal.
In one embodiment, the intermediate layer 61 is formed of a material that exhibits a high dielectric constant. In one illustrative embodiment, the material comprises barium titanate. The thickness of intermediate layer 61 is preferably about 3 microns or greater, although smaller or larger thicknesses may also be used. Preferably, the material used for intermediate layer 61 has a dielectric constant (K) of at least about 10, although materials having other dielectric constants may also be used.
By providing the intermediate layer 61 having a high dielectric constant, the electrode essentially operates as a parallel-plate capacitor, thereby alleviating the polarization artifact at the electrode/tissue interface. Inclusion of intermediate layer 61 therefore serves to remove at least a portion of the charge from the electrode/tissue interface.
Polarization-reducing outer layer 62 provides a fractal surface structure and relatively large surface area, which increases the capacitance at the interface between layers 61 and 62 and serves to further reduce the polarization artifact at the electrode/tissue interface. In one illustrative embodiment, outer layer 62 is formed of titanium nitride, although other porous structures may also be used, such as iridium oxide, platinum black, and the like. In one illustrative embodiment, the thickness of outer layer 62 is between about 3 and about 12 microns, although other thicknesses may be used.
In a bipolar configuration, ring electrode 39 can be formed having the same three layers 60, 61, and 62 as tip electrode 34, or may be any conventional electrode. In addition, in a unipolar configuration (i.e., with the housing 40 used as the return electrode) the three-layer electrode described hereinabove may be either the tip electrode or a proximal electrode.
Thus, the novel electrode design described herein may be used in various configurations. By way of example, the electrode can be used in a bipolar configuration with a conventional electrode, in a bipolar configuration with an identical electrode, in a unipolar configuration where the novel electrode is the tip electrode, or in a unipolar configuration where the novel electrode is proximal to the distal tip of lead 22.
Because the novel electrode disclosed herein provides relatively low polarization artifacts, the electrode is suitable both for stimulating heart tissue and for sensing cardiac activity following the delivery of stimulation energy to the heart tissue. For example, in a bipolar configuration, the tip electrode 34 preferably is formed with the novel three-layer construction described herein, because that electrode will contact heart tissue and will therefore define an electrode/tissue interface. The proximal electrode 39 may be either a conventional electrode or formed having the same three-layer construction as electrode 34. Stimulation pulses may be delivered between electrodes 34 and 39, and subsequent cardiac activity may be sensed between those same electrodes, or between electrode 34 and a different electrode.
It should be understood that the foregoing description is only illustrative of various embodiments. Various alternatives and modifications can be devised by those skilled in the art. For example, while lead 22 is shown in
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2960642 *||Apr 17, 1958||Nov 15, 1960||Quartz & Silice S A||Dielectric films and capacitors employing the same|
|US3292062 *||Jun 1, 1964||Dec 13, 1966||Bell Telephone Labor Inc||Method for preparing stabilized barium titanate, and capacitor|
|US4628933 *||Jul 23, 1985||Dec 16, 1986||Michelson Robin P||Method and apparatus for visual prosthesis|
|US4679572||Mar 11, 1986||Jul 14, 1987||Intermedics, Inc.||Low threshold cardiac pacing electrodes|
|US5318572||Jun 2, 1992||Jun 7, 1994||Siemens Pacesetter, Inc.||High efficiency tissue stimulating and signal sensing electrode|
|US5628778||Nov 21, 1994||May 13, 1997||Medtronic Inc.||Single pass medical electrical lead|
|US5645580||Jul 21, 1994||Jul 8, 1997||Pacesetter, Inc.||Implantable medical device lead assembly having high efficiency, flexible electrode head|
|US5851896||Jun 7, 1995||Dec 22, 1998||Texas Instruments Incorporated||Conductive exotic-nitride barrier layer for high-dielectric-constant material electrodes|
|US5935158||Aug 21, 1997||Aug 10, 1999||Pacesetter Ab||Electrode lead and device for tissue stimulation and/or detection of tissue response|
|US5964794 *||Mar 20, 1997||Oct 12, 1999||Biotronik Mess- Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin||Implantable stimulation electrode|
|US5995876||Feb 3, 1997||Nov 30, 1999||Medtronic, Inc.||Single pass medical electrical lead|
|US6240320||Jun 5, 1998||May 29, 2001||Intermedics Inc.||Cardiac lead with zone insulated electrodes|
|US6253110||Apr 27, 1999||Jun 26, 2001||Medtronic Inc||Method for tissue stimulation and fabrication of low polarization implantable stimulation electrode|
|US6292704||Aug 27, 1999||Sep 18, 2001||Impulse Dynamics N. V.||High capacitance myocardial electrodes|
|US6339723||Jan 20, 2000||Jan 15, 2002||Pacesetter, Inc.||Method and apparatus for preventing atrial fusion during automatic pacing threshold determination in a cardiac stimulation device|
|US20030220677 *||May 22, 2002||Nov 27, 2003||Doan Phong D.||Implantable coronary sinus lead and lead system|
|US20040176828 *||Mar 3, 2004||Sep 9, 2004||O'brien Robert C.||Low polarization coatings for implantable electrodes|
|US20050075709 *||Feb 18, 2003||Apr 7, 2005||Medtronic, Inc.||Biomedical electrode of enhanced surface area|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7792585||Sep 7, 2010||Pacesetter, Inc.||Expedited set-up of multi-electrode lead (MEL)|
|US8180456||May 15, 2012||Pacesetter, Inc.||Systems and methods to configure a multi-electrode lead|
|US8233979||Mar 21, 2007||Jul 31, 2012||Pacesetter, Inc.||Distributed anode cardiac pacing and sensing|
|US9119956 *||Nov 20, 2013||Sep 1, 2015||Cardiac Pacemakers, Inc.||Medical electrodes with layered coatings|
|US9180289||Aug 9, 2013||Nov 10, 2015||Cardiac Pacemakers, Inc.||Enhanced low friction coating for medical leads and methods of making|
|US20100312298 *||Dec 9, 2010||Christopher Pontiga||Systems and methods to configure a multi-electrode lead|
|US20140142670 *||Nov 20, 2013||May 22, 2014||Cardiac Pacemakers, Inc.||Medical electrodes with layered coatings|
|WO2014081893A2 *||Nov 20, 2013||May 30, 2014||Cardiac Pacemakers, Inc.||Medical electrodes with layered coatings|
|WO2014081893A3 *||Nov 20, 2013||Aug 28, 2014||Cardiac Pacemakers, Inc.||Medical electrodes with layered coatings|
|U.S. Classification||607/121, 607/122|
|May 21, 2003||AS||Assignment|
Owner name: PACESETTER, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHITRE, YOUGANDH;REEL/FRAME:014107/0215
Effective date: 20030519
|Apr 23, 2010||FPAY||Fee payment|
Year of fee payment: 4
|Apr 23, 2010||SULP||Surcharge for late payment|
|Apr 17, 2014||FPAY||Fee payment|
Year of fee payment: 8